Answers are grounded in this paper and cite their sources.
Attachment of the human tissue plasminogen activator signal peptide (tPA-SP) to a variety of proteins has enhanced the induction of both antibody and cellular immune responses in animal models. Here, as part of a continuing effort to improve HIV-1 vaccine immunogenicity, we sought to determine whether or not addition of optimized tPA-SP improves the magnitude and functionality of T cells elicited by vaccines expressing protein HIVconsv derived from highly conserved regions of the HIV-1 proteome. The HIVconsv vaccines were vectored by plasmid DNA, non-replicating simian (chimpanzee) adenovirus ChAdV63 and non-replicating poxvirus MVA. We found that addition of the tPA-SP increased levels of intracellular HIVconsv protein for all the tested vaccines. When administered intramuscularly to the BALB/c mice, a 2- to 3.5-fold increase in frequencies of vaccine-elicited T-cells were observed for the DNA modality, however, there was no consistent significant improvement when using a much more potent heterologous regimen of ChAdV63 prime-MVA boost. Our results concur with previous DNA studies and emphasize that immunopotentiation by the tPA-SP is likely immunogen, vaccine modality, type of immune responses and species specific. Thus, the tPA-SP effect on induction of desired immune responses should be assessed for each vaccine strategy separately.
No takes yet. Share an insight, caveat, or question.
BO Ondondo (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: